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Background: Due to its high expression in prostate cancer, PSMA (prostate-specific membrane antigen) represents
an ideal target for both diagnostic imaging and endoradiotherapeutic approaches. Based on a previously published
highly specific PSMA ligand ([68Ga]DOTA-FFK(Sub-KuE)), we developed a corresponding metabolically stable
1,4,7,10-tetraazacyclododececane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) construct for theranostic treatment
of prostate cancer.
Methods: All ligands were synthesized by a combined solid phase and solution phase synthesis strategy. The affinity of
the natgallium and lutetium complexes to PSMA and the internalization efficiency of the radiotracers were determined
on PSMA-expressing LNCaP cells. The 68Ga- and 177Lu-labelled ligands were further investigated for lipophilicity, binding
specificity, metabolic stability, as well as biodistribution and μPET in LNCaP-tumour-bearing mice.
Results: Radiochemical yields for 68Ga (3 nmol, 5.0 M NaCl/2.7 M HEPES (approximately 5/1), pH 3.5 to 4.5, 5 min, 95°C)
and 177Lu labelling (0.7 nmol, 0.1 M NH4OAc, pH 5.5, 30 min, 95°C) were almost quantitative, resulting in specific
activities of 250 to 300 GBq/μmol for the 68Ga analogues and 38 GBq/μmol for 177Lu complexes. Due to metabolic
instability of L-amino acid spacers, D-amino acids were implemented resulting in a metabolically stable DOTAGA
ligand. Compared to the DOTA ligand, the DOTAGA derivatives showed higher hydrophilicity (logP = −3.6 ± 0.1
and −3.9 ± 0.1 for 68Ga and 177Lu, respectively) and improved affinity to PSMA resulting in an about twofold increased
specific internalization of the 68Ga- and 177Lu-labelled DOTAGA analogue. Especially, [68Ga]DOTAGA-ffk(Sub-KuE)
exhibits favourable pharmacokinetics, low unspecific uptake and high tumour accumulation in LNCaP-tumour-bearing
mice.
Conclusions: The pair of diagnostic/therapeutic PSMA-ligands [68Ga/177Lu]DOTAGA-ffk(Sub-KuE) possess remarkable
potential for the management of prostate cancer.
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Prostate-specific membrane antigen (PSMA, EC 3.4.17.21,
synonym: glutamate carboxypeptidase II) is an extracellu-
lar hydrolase whose catalytic centre comprises two zinc(II)
ions with a bridging hydroxido ligand [1]. It is highly up-
regulated in metastatic and hormone-refractory prostate
carcinomas, but its endogenous expression has also been* Correspondence: martina.weineisen@tum.de
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in any medium, provided the original work is preported in kidneys, salivary glands, small intestine, brain
and, to a low extent, also in healthy prostate tissue [2,3].
In the intestine, PSMA facilitates absorption of folate by
conversion of pteroylpoly-γ-glutamate to the pteroylgluta-
mate (folate) [4]. In the brain, it hydrolyses N-acetyl-L-
aspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and
glutamate [5]. The enzymatic function of PSMA in normal
and diseased prostate has not been clarified yet [6]. How-
ever, due to its overexpression on prostate cancer cells,
PSMA represents an excellent target for molecular im-
aging and targeted radiotherapy of prostate cancer.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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2001 [7], a variety of PSMA-targeted radioligands for
imaging of prostate cancer were developed. The first
PSMA inhibitors radiolabelled with 11C, 18 F and 123/125I
used the X-urea-Glu (XuE)-scaffold (Figure 1, [8-13]).
All of them show high affinity to PSMA and specific
tumour accumulation, demonstrating the suitability of
this class of compounds as imaging probes. Subse-
quently, 99mTc-labelled analogues [14,15] were developed
to provide a generator produced PSMA imaging agent
for SPECT.
Recently, it has been demonstrated that the affinity of
KuE-derived inhibitors is enhanced by extending the
KuE-binding unit by an aromatic moiety, presumably
due to an additional inhibitor-enzyme interaction via π/
π-stacking of the additional aromatic residues with a re-
mote arene-binding pocket [16]. There is apparently an
optimal distance between the KuE-inhibitor component
and the additional arene moiety, leading to an enhance-
ment of PSMA affinity (KD = 13.8 nM) by a factor of up
to 5 [15].
These findings were recently integrated into the design of
68Ga-labelled PSMA ligands (Figure 2), such as [68Ga]
DOTA-FFK(Sub-KuE) [17] and [68Ga]HBED-CC-Ahx-KuE
[18]. Compared to [68Ga]DOTA-FFK(Sub-KuE), [68Ga]
HBED-CC-Ahx-KuE showed higher tumour accumulation
and improved imaging contrast [18]. Unfortunately, the
HBED-CC chelator (N,N′-bis[2-hydroxy-5-(carboxyethyl)
benzyl] ethylenediamine-N,N′-diacetic acid) is not suitable
for radiolabelling with therapeutic radiometals, whereas
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) and its analogues form stable complexes with a
broad range of radiometals, for therapy most importantly
90Y and 177Lu. Given the high expression of PSMA on theFigure 1 Structures of selected PSMA ligands. Depicted are the first 11C-
(X = C, Y, K or E).majority of prostate cancers, the availability of high-affinity
PSMA-targeted probes, labelled with therapeutic radioiso-
topes, offers promising perspectives for PSMA-targeted
endoradiotherapy.
Monoclonal anti-PSMA-antibodies labelled with thera-
peutic radionuclides such as 131I, 90Y and 177Lu, which
are currently being evaluated in clinical trials (clinical-
trials.gov Identifier: NCT00006380, NCT00081172) already
demonstrate promising tumour targeting, acceptable tox-
icity and therapeutic efficiency in humans [19-22].
Amongst the currently available small-molecule PSMA
inhibitors, only [131I]MIP-1375 [23] and [131I]MIP-1466
[24] (Figure 1) have been evaluated in therapy studies so
far. In LNCaP-tumour-bearing nude mice, [131I]MIP-
1375 inhibited tumour growth in a time- and dose-
dependent manner. First, human applications of [131I]
MIP-1095/1466 revealed promising therapy response
with moderate side effects [25]. The structurally corre-
sponding diagnostics, 123I-labelled analogues [123I]MIP-
1072 and [123I]MIP-1095, were shown to possess suitable
characteristics for SPECT imaging. However, these com-
pounds are comparably lipophilic (clogP = 0.20 and 1.97,
respectively [25]), and their compact structure compli-
cates further optimization of PSMA affinity and pharma-
cokinetics. Furthermore, PET imaging is only possible
using 124I, a suboptimal PET-radionuclide with respect
to resolution and dosimetry.
In contrast, radiometalated analogues based on the
FFK(Sub-KuE)-scaffold represent a much more flexible
and finely adjustable backbone for the development of
KuE-based PSMA inhibitors, that allow labelling with
both diagnostic and therapeutic radionuclides, e.g. 68Ga
for PET imaging and 177Lu/90Y for therapy after conju-
gation of DOTA. However, in order to further facilitatelabelled and radiohalogenated PSMA ligands based on the XuE-scaffold
Figure 2 Previously reported PSMA ligands for 68Ga labelling [17,18]. Both compounds were included as references in this study.
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pharmacokinetics, and potentially obtain radiometalated
derivatives with higher affinity, we substituted DOTA in
DOTA-FFK(Sub-KuE) by 1,4,7,10-tetraazacyclodocecane,1-
(glutaric acid)-4,7,10-triacetic acid (DOTAGA) [26,27].
Improved affinities, higher tumour uptake and faster
kidney clearance have already been observed for the 68Ga-
complex (one free carboxylate) compared to the 90Y-com-
plex (all carboxylates coordinated) of DOTA-coupled
somatostatin analogues before [28].
Consequently, we evaluated and compared the respect-
ive 68/natGa- and 177/natLu-DOTAGA analogues of FFK
(Sub-KuE) and ffk(Sub-KuE) in terms of PSMA affinity,
uptake in PSMA positive tumour cells, metabolic stability,
in vivo biodistribution and μPET imaging. The previously
described DOTA analogues [17] and [68Ga]HBED-CC-
Ahx-KuE [18] were also included to allow direct compar-
ability of our results with the data in the literature.
Methods
General
Fmoc-(9-fluorenylmethoxycarbonyl-) and all other pro-
tected amino acid analogues were purchased from Iris
Biotech (Marktredwitz, Germany) or Bachem (Bubendorf,
Switzerland). Tritylchloride polystyrene (TCP) resin
was obtained from PepChem (Tübingen, Germany). The
chelators DOTA-tris-tBu-ester and DOTAGA-anhydride
were purchased from Chematech (Dijon, France). Solvents
and all other organic reagents were purchased from Sigma-
Aldrich (Munich, Germany) or CLN (Freising, Germany).
Solid phase peptide synthesis was carried out manually
using an Intelli-Mixer syringe shaker (Neolab, Heidelberg,
Germany). Analytical reversed-phase high performance
liquid chromatography (RP-HPLC) was performed on a
Nucleosil 100 C18 (5 μm, 125 × 4.0 mm) column (CS
GmbH, Langerwehe, Germany) using a Sykam gradientHPLC System (Sykam GmbH, Eresing, Germany). The pep-
tides were eluted applying different gradients of 0.1% (v/v)
trifluoroacetic acid (TFA) in H2O (solvent A) and 0.1%
TFA (v/v) in acetonitrile (solvent B) at a constant flow of
1 mL/min (specific gradients are cited in the text). UV
detection was performed at 220 nm using a 206 PHD
UV-Vis detector (Linear™ Instruments Corporation, Reno,
USA). Both retention times tR as well as the capacity factors
K' are cited in the text. Preparative RP-HPLC was per-
formed on the same HPLC system using a Multospher 100
RP 18-5 (250 × 20 mm) column (CS GmbH, Langerwehe,
Germany) at a constant flow of 9 mL/min. Radio-HPLC of
the radioiodinated reference ligand was carried out using a
Nucleosil 100 C18 (5 μm, 125 × 4.0 mm) column. For
radioactivity detection, the outlet of the UV-photometer
was connected to a NaI(Tl) well-type scintillation coun-
ter from EG&G Ortec (Munich, Germany). Analysis of
68Ga-labelled compounds was done as described previ-
ously [29]. ESI-mass spectra were acquired on a Varian
500-MS IT mass spectrometer (Agilent Technologies,
Santa Clara, USA).
Synthesis of carboxyl-protected Lys-urea-Glu-core (KuE)
(S)-di-tert-butyl 2-(1H-imidazole-1-carboxamido)penta-
nedioate (1) was synthesized as described previously
[12]. HPLC (10% to 90% B in 15 min): tR = 12.2 min; K′ =
5.78. Calculated monoisotopic mass for 1 (C17H27N3O5):
353.4; found: m/z = 376.0 [M+Na]+.
Cbz-(OtBu)KuE(OtBu)2 (2): A solution of 3.40 g
(9.64 mmol, 1.0 eq) 1 in 45 mL 1,2-dichloroethane
(DCE) was cooled to 0°C, and 2.69 mL (19.28 mmol,
2.0 eq) of triethylamine (TEA), and 3.59 g (9.64 mmol,
1.0 eq) of Cbz-Lys-OtBu · HCl was added under vigorous
stirring. The reaction mixture was heated to 40°C over-
night. The solvent was removed in vacuo, and the crude
product was purified via silica gel flash-chromatography
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(500/500/0.8 (v/v/v)). Upon solvent evaporation, 4.80 g
of 2 were obtained as a colourless, sticky oil (yield: 80%
based on L-di-tert-butyl glutamate · HCl). HPLC (40% to
100% B in 15 min): tR = 14.3 min; K′ = 8.53. Calculated
monoisotopic mass for 2 (C32H51N3O9): 621.8; found:
m/z = 622.2 [M +H]+, 644.3 [M +Na]+.
(OtBu)KuE(OtBu)2 (3): For Cbz deprotection, 6.037 g
(9.71 mmol, 1.0 eq) of 2 was dissolved in 150 mL of
ethanol (EtOH), and 0.6 g (1.0 mmol, 0.1 eq) of Palla-
dium on activated charcoal (10%) was added. After pur-
ging the flask with H2, the solution was stirred overnight
under light H2-pressure (balloon). The crude product
was filtered through Celite, the solvent was evaporated
in vacuo, and the desired product was obtained as a
waxy solid (4.33 g, 91.5% yield). HPLC (10% to 90% B in
15 min): tR = 12.6 min; K′ = 6.41. Calculated monoisoto-
pic mass for 3 (C24H45N3O7): 487.6; found: m/z = 488.3
[M +H]+, 510.3 [M +Na]+.Synthesis of protected Sub-KuE conjugate
NHS-Sub-(OtBu)KuE(OtBu)2 (4): 3 (40 mg, 0.08 mmol,
1 eq) was dissolved in 500 μLN,N-dimethylformamide
(DMF), and 57 μL (0.41 mmol, 5 eq) of TEA was added.
This solution was added dropwise (within 30 min) to a
solution of 33.2 mg (0.09 mmol, 1.1 eq) of disuccinimi-
dyl suberate (DSS). After stirring for an additional 2 h at
room temperature (RT), the reaction mixture was con-
centrated in vacuo, diluted with ethyl acetate and ex-
tracted with water (twice). The organic phase was dried
over Na2SO4, filtered and evaporated to dryness. Due to
sufficient purity of the crude 4, it was used for the fol-
lowing reaction step without further purification. HPLC
(10% to 90% B in 15 min): tR = 16.9 min; K′ = 8.39.
Calculated monoisotopic mass for 4 (C36H60N4O12):
740.4; found: m/z = 741.2 [M +H]+, 763.4 [M +Na]+.Synthesis of peptidic spacers
Fmoc-L-Phe-L-Phe-L-Lys(Boc) (Fmoc-FFK, 5) and
Fmoc-D-Phe-D-Phe-D-Lys(Boc) (Fmoc-ffk, 6): Fmoc-Lys
(Boc)-OH was coupled to TCP resin according to a
previously published method [30]. Briefly, Fmoc-Lys
(Boc)-OH (1.5 eq) was dissolved in dry dichloromethane
(DCM), and N,N-diisopropylethylamine (DIPEA) (1.25 eq)
was added. Dry TCP resin was suspended and stirred
at RT for 5 min. Another 2.5 eq of DIPEA was added,
and stirring was continued for 90 min. Then, 1 mL
methanol (MeOH) per gram resin was added to cap
unreacted Tritylchloride groups. After 15 min, the
resin was filtered off, washed twice with DCM, DMF
and MeOH, respectively, and dried in vacuo. Final
load of resin-bound Fmoc-Lys(Boc)-OH was calcu-
lated from the weight difference.Assembly of the peptide sequence H2N-Phe-Phe- on
resin-bound Lys(Boc) was performed according to a stand-
ard Fmoc-protocol using 1.5 eq of 1-hydroxybenzotriazole
(HOBt) and O-(1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethy-
luronium-tetrafluoroborate (TBTU) as coupling reagents
and 4.5 eq DIPEA. After coupling of the last amino acid,
the resin was washed, dried and stored in a desiccator
until further functionalization.
Coupling of chelating moiety
Fmoc-Phe-Phe-Lys(Boc)-TCP resin was allowed to pre-
swell in N-methyl-pyrrolidon (NMP) for 30 min. After
cleavage of the N-terminal Fmoc-protecting group using
20% piperidine in DMF (v/v), the resin was washed eight
times with NMP. The coupling of the respective chelators
is described below. Cleavage from the resin (2 × 30 min)
and concomitant tBu-deprotection was performed using a
mixture (v/v/v) of 95% TFA, 2.5% triisobutylsilane (TIBS)
and 2.5% water. The combined product solutions were
then concentrated, the crude peptide was precipitated
using diethyl ether and was dried in vacuo. Due to suffi-
cient purity of the crude products, they were used for the
following reaction step without further purification.
DOTA-Phe-Phe-Lys (DOTA-FFK, 7) [17]: For 38 μmol
of resin-bound peptide, 33 mg of DOTA-tris-tBu-ester
(57 μmol, 1.5 eq), 108 mg of O-(7-azabenzotriazol-1-yl)-N,
N,N′,N′-tetramethyluronium hexafluorophosphate (HATU;
0.28 μmol, 5 eq) and 87 μL of DIPEA (570 μmol, 15 eq) in
NMP were added to the resin. After 72 h of shaking, the
resin was washed with NMP and DCM. HPLC (10% to
90% B in 15 min): tR = 8.2 min; K′ = 4.13. Calculated mon-
oisotopic mass for 7 (C40H58N8O11): 826.4; found: m/z =
827.3 [M+H]+, 849.3 [M+Na]+, 414.2 [M +2H]2+.
DOTAGA-Phe-Phe-Lys (DOTAGA-FFK, 8 and DOTAGA-
ffk, 9): For 0.27 mmol peptide-bound resin, 190 mg
DOTAGA-anhydride (0.42 mmol, 1.5 eq) and 470 μL
DIPEA (2.7 mmol, 10 eq) in NMP were added to the resin.
After 18 h of shaking, the resin was washed with NMP
and DCM. HPLC (10% to 90% B in 15 min): tR =
10.6 min; K′ = 5.63. Calculated monoisotopic mass for 8
and 9 (C43H62N8O13): 898.4; found: m/z = 899.4 [M +H]
+,
921.4 [M+Na]+, 450.2 [M +2H]2+.
Condensation of the chelator-conjugated peptides and
the PSMA binding motif
DOTA-FFK(Sub-KuE) (10) [17]: To a solution of 7
(15 mg, 18 μmol, 1 eq) and TEA (13 μL, 90 μmol, 5 eq)
dissolved in 600 μL of DMF was slowly added 13 mg of
4 (18 μmol, 1 eq) dissolved in 400 μL of DMF. After stir-
ring for 2 h at RT, the reaction mixture was evaporated
to dryness. Subsequent removal of tBu-protecting groups
was carried out by dissolving the crude product in TFA
and stirring for 40 min. After precipitation in diethyl
ether, the crude product was dissolved in water and
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20 min). HPLC (10% to 90% B in 15 min): tR =
10.3 min; K′ = 5.44. Calculated monoisotopic mass for
10 (C60H89N11O20): 1,283.6; found: m/z = 1,284.5 [M+H]
+,
1,306.7 [M+Na]+, 642.8 [M +2H]2+.
DOTAGA-FFK(Sub-KuE) (11) and DOTAGA-ffk(Sub-
KuE) (12): Either 8 or 9 (21 mg, 30 μmol, 1 eq) was
added to TEA (21 μL, 150 μmol, 5 eq) and 27 mg of 4
(30 μmol, 1 eq) as described for 10. HPLC (10% to 90%
B in 15 min): tR = 9.7 min; K′ = 4.11. Calculated mono-
isotopic mass for 11 and 12 (C63H93N11O22): 1,355.7;
found: m/z = 1,356.2 [M +H]+, 1,378.2 [M +Na]+, 679.2
[M +2H]2+.
Synthesis of the radioiodination precursor (13)
The synthesis was performed according to previously
published methods [12,31,32].
Succinimidyl-4-iodobenzoate (I-BA-NHS, 14): Under a
nitrogen atmosphere, 500 mg (2.0 mmol, 1.0 eq) 4-
iodobenzoic acid was dissolved in 10 mL DCM, and
after addition of 278 mg (2.4 mmol, 1.2 eq) N-hydroxy-
succinimide and 374 mg (1.81 mmol, 0.9 eq) dicyclohexyl
carbodiimide, the suspension was stirred overnight. The
precipitate was filtered off, and the filtrate was evaporated
to dryness. The resulting solid was washed with a 1:1-mix-
ture of DCM and hexane to yield the desired product
(583.5 mg, 93%) as a white solid. Due to the limited de-
tectability of the product in ESI-mass spectrometry (MS),
a representative conjugate with H-Phe-OtBu (1 eq) was
prepared in DMF in the presence of DIPEA (3 eq) and
characterized via MS. HPLC (40% to 100% B in 15 min):
tR = 10.6 min; K' = 5.63. Calculated monoisotopic mass for
I-BA-Phe(OtBu) (C20H22INO3): 451.1; found: m/z = 396.1
[M+H-tBu]+.
Succinimidyl-4-tributylstannyl-benzoate (SnBu3-BA-
NHS, 15): To a solution of 100 mg (0.29 mmol, 1.0 eq)
14 in 5 mL anhydrous toluene were added 234 μL
(0.464 mmol, 1.6 eq) of hexabutylditin and 10.7 mg
(9 μmol, 0.02 eq) of the catalyst tetrakis(triphenylpho-
sphine)palladium under a nitrogen atmosphere. The mix-
ture was heated under reflux until the solution turned
black (overnight). After cooling, the toluene was removed
in vacuo, and the resulting oil was purified using silica gel
flash chromatography (ethyl acetate/hexane: 3/7 (v/v)) to
yield 15 (78 mg, 53%) as a colourless oil. TLC (ethyl acet-
ate/hexane: 3/7): Rf = 0.46
(SnBu3-BA)(OtBu)KuE(OtBu)2 (13): To a solution of
19.0 mg (0.039 mmol, 1.0 eq) 3 in 2 mL DCM were
added 26.3 μL (0.187 mmol, 4.8 eq) of TEA and 19.8 mg
(0.039 mmol, 1.0 eq) of 15. The mixture was stirred at
RT for 4 h and was then diluted with DCM. After wash-
ing with water, the organic phase was dried over
Na2SO4, filtered and evaporated to dryness. 13 (30.8 mg,
89.7%) was obtained as a colourless oil. HPLC (10% to90% B in 15 min): tR = 23.8 min; K' = 13.88. Calculated
monoisotopic mass for 13 (C43H75N3O8Sn): 880.8;
found: m/z = 902.2/903.3/904.3 [M +Na]+.
Synthesis of unlabelled reference compounds
(I-BA)KuE: To a solution of 15 mg (0.031 mmol,
1.0 eq) 3 in 2 mL DMF was added 11.4 mg
(0.046 mmol, 1.5 eq) of 4-iodo-benzoic acid, 6.3 mg
(0.046 mmol, 1.5 eq) of 1-Hydroxy-7-azabenzotriazole
(HOAt), 7.2 μL (0.046 mmol, 1.5 eq) diisopropyl car-
bodiimide (DIC) and 23.7 μL (0.138 mmol, 4.5 eq)
DIPEA. The yellow solution was stirred for 20 h, di-
luted with ethyl acetate and extracted with water. The
organic layer was dried over Na2SO4, filtered and
evaporated to dryness. For tBu-deprotection, the crude
product was dissolved in 200 μL TFA. After 30 min,
the solvent was evaporated and the crude product was
purified using preparative RP-HPLC (isocratic eluent:
18% B). HPLC (10% to 90% B in 15 min): tR =
10.5 min; K′ = 5.56 calculated monoisotopic mass for
(I-BA)KuE (C19H24IN3O8): 549.3; found: m/z = 550.0
[M + H]+, 571.9 [M + Na]+
natGa compounds: For the preparation of the natGa
complexes, equal volumes of a 2 mM solution of Ga
(NO3)3 in water and a 2 mM solution of the respective
PSMA ligand in water were mixed and heated to 40°C
for 30 min. After cooling, the natGaIII-chelate formation
was confirmed using RP-HPLC and MS. The resulting
1 mM aqueous solutions of the respective natGa-com-
plexes were then further diluted and used in the in vitro
IC50 studies without further processing.
[natGa]DOTA-FFK(Sub-KuE) (natGa-10) HPLC (20%
to 60% B in 15 min): tR = 11.6 min; K′ = 6.3. Ccalcu-
lated monoisotopic mass (C60H86N11O20Ga): 1,349.5;
found: m/z = 1,350.3 [M + H]+, 1,372.1 [M + Na]+,
675.7 [M +2H]2+.
[natGa]DOTAGA-FFK(Sub-KuE) (natGa-11) HPLC (25%
to 45% B in 15 min): tR = 16.0 min; K′ = 9.0. Calculated
monoisotopic mass (C63H90N11O22Ga): 1,421.7, 1,423.7;
found: m/z = 1,422.1/1,424.1 [M + H]+, 710.6/712.6
[M +2H]2+.
[natGa]DOTAGA-ffk(Sub-KuE) (natGa-12) HPLC (25%
to 55% B in 15 min): tR = 12.1 min; K′ = 7.6. Calculated
monoisotopic mass (C63H90N11O22Ga): 1,421.7, 1,423.7;
found: m/z = 1,422.6/1,424.5 [M +H]+, 1,444.4/1,446.4
[M +Na]+.
[natGa]HBED-CC-Ahx-KuE HPLC (25% to 43% B in
15 min): tR = 9.0 min; K′ = 5.0. Calculated monoisotopic
mass (C44H59N6O17Ga): 1,012.3, 1,014.3; found: m/z =
1,013.0/1,015.0 [M +H]+, 1,035.0/1,037.0 [M +Na]+.
natLu-compounds: The corresponding natLuIII com-
plexes were prepared with a 2.5-molar excess of Lu3+,
heated at 95°C for 30 min and evaluated similar to the
natGaIII complexes.
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45% B in 16 min): tR = 14.1 min; K′ = 9.1. Calculated
monoisotopic mass (C60H86N11O20Lu): 1,455.6; found:
m/z = 1,456.4 [M +H]+, 1,478.5 [M +Na]+.
[natLu]DOTAGA-FFK(Sub-KuE) (natLu-11) HPLC
(25% to 45% B in 16 min): tR = 14.4 min; K′ = 9.3. Cal-
culated monoisotopic mass (C63H90N11O22Lu): 1,527.6;
found: m/z = 1,528.4 [M +H]+, 1,550.3 [M +Na]+, 764.2
[M +2H]2+.
[natLu]DOTAGA-ffk(Sub-KuE) (natLu-12) HPLC (25%
to 55% B in 15 min): tR = 10.4 min; K′ = 6.4. Calculated
monoisotopic mass (C63H90N11O22Lu): 1,527.6; found:
m/z = 1,528.1 [M +H]+, 764.5 [M +2H]2+.
Radiolabelling
([125I]I-BA)KuE: The radioiodination was performed ac-
cording to previously published methods [12,31,32]. Per-
acetic acid was prepared by mixing 130 μL of H2O2
(30%) and 50 μL of acetic acid. After a 2 h-incubation
period, 20 μL peracetic acid solution and 5 μL (21.0 MBq)
[125I]NaI (74 TBq/mmol, 3.1 GBq/mL 40 mM NaOH,
Hartmann Analytic, Braunschweig, Germany) was added
to a solution of approximately 0.1 mg 15 in 20 μL MeCN/
acetic acid (1/1) and incubated at RT for 10 min. The
product was diluted with 10 mL of water and loaded onto
a C18 Sep Pak Plus cartridge, which had been precondi-
tioned with 10 mL of MeOH and rinsed with 10 mL of
water. The cartridge was then washed with 10 mL water,
and the product was eluted in 300 to 500 μL fractions with
a 1:1 mix (v/v) of EtOH/MeCN (2 mL). The radioactive
fractions were evaporated to dryness, and the residue was
dissolved in 200 μL TFA. After 30 min, the solvent was
evaporated in vacuo. The crude product was isolated from
unlabelled tributyltin precursor by RP-HPLC (20% to 40%
B in 20 min) to afford the desired product (10.9 MBq).
HPLC (20% to 40% B, 220 nm): tR = 13.0 min, K′ = 6.22.
68Ga-labelling: A 1.25 mL fraction of 68Ge/68Ga gener-
ator (iTHEMBA Labs, South Africa) eluate (1 M HCl)
was loaded onto a self-filled cartridge containing 300 mg
SCX material (Bond Elut-SCX, Varian). The cartridge
was then washed with water (1.0 mL) and purged with
air. The 68Ga3+ was eluted with aq. NaCl (5 M, 0.5 mL)
and HEPES (2.7 M aq., 90 or 140 μL) was added (pH 3.5
or 4.5, respectively). That solution was mixed with the
precursor (3 nmol in 10 μL) and heated at 95°C for
5 min. After cooling, labelling efficiency and radiochem-
ical purity were determined using Radio-TLC and
Radio-HPLC. Radiochemical purity of all 68Ga-labelled
conjugates was ≥95%. Therefore, the tracers were diluted
and used in vitro experiments without further purifica-
tion. Tracers for in vivo use were prepared in GMP-
compliant procedure using a fully automated synthesis
module (Scintomics GmbH, Germany) similar to the
procedure described previously [33]. For animal studies,the EtOH for eluting the labelled tracer from a SPE cart-
ridge was evaporated in vacuo.
177Lu-labelling: A 0.1 mM aqueous solution of chelator-
coupled peptide (0.66 nmol) was added to 25 MBq [177Lu]
LuCl3 (170 GBq/μmol, 17 GBq/mL 0.05 M HCl, IDB
Radiopharmacy bv). The pH was adjusted to pH 5 by the
addition of approximately 150 μL 0.1 M NH4OAc solu-
tion. After 45 min at 95°C, the labelling efficiency was ex-
amined by TLC and RP-HPLC.
Determination of lipophilicity
To a solution of 0.5 to 1 MBq of radiolabelled peptide in
500 μl of phosphate-buffered saline (PBS, pH 7.4),
500 μl of n-octanol was added (n = 6). Vials were vor-
texed vigorously for 3 min. To achieve quantitative
phase separation, the vials were centrifuged at 6,000 g
for 5 min in a Biofuge 15 (Heraeus Sepatech, Osterode,
Germany). The activity concentrations in 100 μl-samples
of both the aqueous and the organic phase were mea-
sured in a γ-counter. Both the partition coefficient P(o/
w), which is defined as the molar concentration ratio of a
single species A between n-octanol and water at equilib-
rium, and logP(o/w), which is an important parameter
used to characterize lipophilicity of a compound, were
calculated.
Metabolite analysis
177Lu-10 and 177Lu-11 were incubated in 80 μL of hu-
man serum (37°C) and 80 μL 0.4 M DTPA solution
(RT), respectively and after 1, 24 and 48 h, the stability
was determined by TLC analysis. The 68Ga-labelled
tracers (40 to 45 MBq) were injected into the tail vein of
CD-1 nu/nu mice. The animals were sacrificed after
30 min, and urine, blood and kidney samples were taken.
The kidney was frozen in liquid nitrogen, homogenized
with a ball mill and extracted with 0.2 to 1 mL PBS con-
taining 200 nmol 2-(phosphonomethyl)pentane-1,5-dioic
acid (PMPA). The suspension was first centrifuged
(15,000 g), and after ultrafiltration, the extracts were
analysed by RP-HPLC. The blood samples were centri-
fuged to separate the plasma from the blood cells.
Plasma proteins were removed by precipitation with
acetonitrile (10 min, 4°C) and subsequent centrifugation
and ultrafiltration. The blood extract was also analysed
by RP-HPLC.
In vitro assays
Cell culture: PSMA+ LNCaP cells (CLS: 300265) were
grown in DMEM/Nutrition Mix F-12 with Glutamax-I
(1:1) (Invitrogen, Life Technologies, Darmstadt, Germany)
supplemented with 10% FCS. Cultures were maintained at
37°C in a 5% CO2/humidified air atmosphere. One day
prior to the experiment, cells were harvested using Tryp-
sin/EDTA (0.05% and 0.02%) in PBS, centrifuged and
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Countesse automated cell counter (Invitrogen, Carlsbad,
USA) was used. All in vitro binding and internalization
studies were performed using live cells seeded 1 day prior
to the experiment. For IC50 determination, 150,000 cells/
mL were transferred to 24-well plates (1 mL/well), and for
internalization studies, 125,000 cells/mL were transferred
into PLL-coated 24-well plates.
Determination of IC50: The culture medium was re-
moved, and the cells were washed once with 500 μL of
HBSS (Hank's balanced salt solution, Biochrom, Berlin,
Germany, containing 1% bovine serum albumin (BSA)),
before being left to equilibrate in 200 μL of HBSS (1%
BSA) on ice for 15 min. Then, 25 μL/well of either HBSS
(1% BSA; control) or of solutions containing the respect-
ive unlabelled ligand of interest in increasing concentra-
tions (10-10-10-4 M in HBSS (1% BSA)) was added,
followed by the addition of 25 μL of ([125I]I-BA)KuE in
HBSS (1% BSA). Experiments were carried out in tripli-
cate for each concentration. The final radioligand con-
centration was 0.2 nM in all binding assays. Cells were
incubated on ice for 60 min. Incubation was terminated
by the removal of the incubation medium. Cells were
thoroughly rinsed with 250 μL of HBSS. The wash
medium was combined with the supernatant of the pre-
vious step. This fraction represents the amount of free
radioligand. Cells were then lysed using 250 μL of 1 N
NaOH, the lysate was transferred to vials and combined
with 250 μL of HBSS used for rinsing the wells. Quanti-
fication of the amount of free and bound activity was
performed in a γ-counter.
Internalization studies: The culture medium was re-
moved, and the cells were washed once with 500 μL
DMEM-F12 (5% BSA) before being left to equilibrate in
200 μL DMEM-F12 (5% BSA) at 37°C for a minimum of
15 min. Then, 25 μL (per well) of either DMEM-F12 (5%
BSA) or of a 100-μM PMPA solution (blocking) was
added, followed by the addition of 25 μL of 68Ga/177Lu-
labelled PSMA ligand. The final radioligand concentra-
tion was 0.2/0.5 nM in all internalization assays. To
determine internalization kinetics, cells were then incu-
bated at 37°C for 5, 15, 30 and 60 min, respectively. Ex-
periments were carried out in triplicate for each time
point (control and blocking). Incubation was terminated
by placing the plate on ice for approximately 1 min and
by subsequent removal of the incubation medium. Cells
were thoroughly rinsed with 250 μL of PBS. The wash
medium was combined with the supernatant of the pre-
vious step. This fraction represents the amount of free
radioligand. To remove receptor surface bound radio-
activity, the cells were then incubated for 10 min with
250 μL of ice cold PMPA solution (10 μM in PBS). After
removal of the supernatant, the cells were thoroughly
rinsed with another 250 μL of ice cold PBS. Bothfractions were combined. The internalized activity was
released by incubation with 250 μL of 1 N NaOH, trans-
ferred to vials and combined with 250 μL of 1 N NaOH
used for rinsing the wells. Quantification of the amount
of free, PMPA-releasable and internalized activity was
performed in a γ-counter.
In vivo experiments
All animal experiments were conducted in accordance
with general animal welfare regulations in Germany
(Deutsches Tierschutzgesetz, approval #55.2-1-54-2532-
71-13). The prostate cancer cell line LNCaP was sus-
pended 1/1 in serum-free medium and Matrigel (BD
Biosciences, Germany) and approximately 107 cells in
200 μL were inoculated subcutaneously on the right
shoulder of 6 to 8 weeks old CD-1 nu/nu mice (Charles
River Laboratories). Tumours were grown for 2 to
4 weeks (males) and 4 to 6 weeks (females) to reach 4 to
8 mm in diameter.
Biodistribution: The 68Ga-labelled PSMA ligands (ap-
proximately 7 to 15 MBq, 0.1 to 0.2 nmol) were injected
into the tail vein of isoflurane anesthetized animals. The
organ distribution was examined 1 h p.i. and quantified
in a γ-counter.
μPET imaging: Imaging studies were performed at a
Siemens Inveon small animal PET, followed by data ana-
lysis using the Inveon Research Workplace software.
The animals were anesthesized with isoflurane and
injected via tail vein with 14 to 18 MBq (0.2 nmol) of
tracer. Dynamic imaging was performed after on-bed in-
jection for 1.5 h. Static images were recorded at 1 h p.i.
with an acquisition time of 15 min. For the blockade
image, animals were coinjected with 8 mg/kg of PMPA.
Images were reconstructed using 3D ordered-subsets ex-
pectation maximum (OSEM3D) algorithm without scan-
ner and attenuation correction.
Results
Chemistry
The tBu-protected PSMA binding motif ((OtBu)KuE
(OtBu)2, 3) was synthesized in 73% yield via three steps
of solution phase chemistry as previously described with
minor modifications (Figure 3, [12]).
The ligands DOTA-FFK(Sub-KuE) (10), DOTAGA-
FFK(Sub-KuE) (11) and DOTAGA-ffk(Sub-KuE) (12)
were prepared according to Figure 4. The peptidic
spacers H-L-Phe-L-Phe-L-Lys(Boc)-OH (FFK(Boc), 5) and
H-D-Phe-D-Phe-D-Lys(Boc)-OH (ffk(Boc), 6) were syn-
thesized via solid phase peptide synthesis using a standard
Fmoc protocol. The prochelators DOTA-tris-tBu-ester
and DOTAGA-anhydride were coupled to the resin-
bound peptides in almost quantitative yields. Subse-
quently, the chelator-conjugated peptides were cleaved
from the resin (TFA/TIBS/H2O) and simultaneously
Figure 3 Synthesis of the PSMA binding motif 3. (a) DCI, TEA, DMAP [DCM]; (b) H-Lys(Z)-OtBu, TEA [DCE]; (c) Pd/C (10%), H2 [EtOH].
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PSMA binding motif 3 was first reacted with DSS
in solution and then coupled with the chelator-
functionalized peptides 7, 8 and 9. After acidic cleav-
age of the remaining tBu-protecting groups, the final
products were purified by RP-HPLC. The products
were obtained in approximately 15% yield (based on
tripeptide). The identity of 10, 11 and 12 was con-
firmed by MS.
The natGaIII and natLuIII complexes of compounds 10,
11 and 12 were prepared by incubation of 10, 11 and 12
with an equimolar amount of aq. Ga(NO3)3 at 40°C for
30 min and an 2.5-molar excess of LuCl3 at 95°C for
30 min, respectively. Quantitative metal complex forma-
tion was confirmed by RP-HPLC and MS.
Radiochemistry
([125I]I-BA)KuE, the reference radioligand in all PSMA
binding assays carried out in this study, was synthesized
in solution starting from 4-iodo-benzoic acid according
to methods described in the literature [12,31,32]. The re-
spective Bu3Sn-precursor 13 was destannylated with
[125I]NaI using peracetic acid as the oxidizing agent
within 10 min at RT. After cartridge purification subse-
quent tBu-deprotection and RP-HPLC purification, the
final product was obtained in a radiochemical yield of
44 ± 5% and radiochemical purity of >99%. The reference
material for chromatographic analyses (cold) (I-BA)KuE
was synthesized by coupling 4-iodo-benzoic acid to 3,
subsequent tBu-deprotection and RP-HPLC purification.
Preparation of 68Ga for labelling of 10, 11 and 12
was performed by combination of previously described
methods [34,35] with minor modifications. The 68Ga3+
eluted with 1 M HCl from a 68Ge/68Ga generator
(iThemba Labs, South Africa) was retained on a strong
cation exchange cartridge followed by elution with
0.5 mL 5M NaCl, resulting in highly concentrated 68Ga
activity. Quantitative 68Ga-complexation was achieved
using 3 nmol of the respective DOTA- or DOTAGA-
conjugated PSMA inhibitors (95°C, 5 min, pH adjusted to
3.5 and 4.5 by addition of 2.7 M HEPES, respectively),
allowing their use in in vitro studies without further purifi-
cation. Specific activities of the 68Ga-labelled PSMA inhib-
itors were 250 to 300 GBq/μmol. The 68Ga-labelling forin vivo biodistribution and PET imaging studies
were carried out using a fully automated GMP-compliant
procedure using a GRP synthesizer (Scintomics GmbH,
Germany) [33]. In these cases, the obtained specific activ-
ities were 80 to 120 GBq/μmol.
To obtain RCY >95% for complexation of 10, 11 and
12 with [177Lu]LuCl3, 0.66 nmol of precursor were
reacted with 25 MBq [177Lu]LuCl3 (AS = 170 GBq/μmol)
at pH 5 (0.1 M NH4OAc, 95°C, 45 min) resulting in spe-
cific activities of AS ≥38 GBq/μmol.
PSMA binding affinity
The PSMA binding affinities were determined in a com-
petitive binding assay using LNCaP human prostate car-
cinoma cells and the known high affinity PSMA ligand
([125I]I-BA)KuE [10] (c = 0.2 nM) as the radioligand.
The IC50 values for the metal-free PSMA-inhibiting
compounds and their respective natGa and natLu com-
plexes are summarized in Table 1. HBED-CC-Ahx-KuE
and [natGa]HBED-CC-Ahx-KuE [12] were included in
this study as reference compounds. The PSMA affinities
of 11 and 12, as well as their respective natGa and natLu
analogues were consistently higher than the affinities of
the respective DOTA constructs (10). Substitution of the
L-amino acids in the linker region of the ligands by
D-amino acids showed only a negligible effect on PSMA
affinity (12 vs 11).
Internalization kinetics and specificity of cell binding
The cellular uptake and internalization kinetics of the
different 68Ga- and 177Lu-labelled PSMA ligands was de-
termined using PSMA-expressing LNCaP cells. In the
case of the 68Ga-labelled compounds, the final peptide
concentration in the assays was 0.2 nM. Since all 177Lu
analogues were obtained in significantly lower specific
activities than the 68Ga analogues, the ligand concentra-
tion had to be increased to 0.5 nM to obtain reasonable
count rates for assay evaluation. All internalization
studies were accompanied by reference studies using
([125I]I-BA)KuE (c = 0.2 nM). This experimental setup
allows data normalization and eliminates the influence
of cell count and cell viability on absolute cellular tracer
uptake. To investigate the specificity of binding to
PSMA, experiments were also carried out in the presence
Figure 4 Modified solid-phase synthesis of the DOTA conjugate 10 [17] and DOTAGA conjugates 11 and 12. (a) 20% piperidine in NMP,
Fmoc-Phe-OH, HOBt, TBTU, DIPEA, [NMP]; (b) 20% piperidine in NMP, DOTA-tris-tBu-ester, HATU, DIPEA [NMP]; (c) 95% TFA, 2.5% TIBS, 2.5% H2O;
(d) 20% piperidine in NMP, DOTAGA-anhydride, DIPEA [NMP]; (e) DSS, TEA [DMF]; (f) 7, TEA [DMF]; (g) TFA; (h) 8, TEA [DMF]; (i) 9, TEA [DMF].
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(1.4 nM, [7]). Furthermore, to be able to discriminate be-
tween total cellular activity (sum of membrane associated
and internalized activity) and internalized activity, all incu-
bations were followed by a washing step with 10 μM
PMPA at 4°C to remove specifically cell-surface bound
radioligand by displacement.
Non-specific binding in the presence of 10 μM PMPA
was lower than 0.5% for all compounds investigated. As
expected, the cellular binding and internalization of allradiometalated PSMA ligands in this study increased
over the time of observation (1 h). For all compounds,
the fraction of internalized activity ranged between 4.5 ±
0.2% and 27.7 ± 1.6% of the total added activity after 1 h.
The fraction of non-internalized, i.e. membrane-bound
activity was 1% to 3% in all experiments (exemplarily
shown for 177Lu-10 and 177Lu-11 in Figure 5).
Variations in cell count and/or cell viability between
experiments can significantly affect the cellular tracer
uptake but cannot be fully avoided. Therefore,
Table 1 PSMA affinities (IC50) of the compounds
investigated
Ligand IC50 [nM]
HBED-CC-Ahx-KuE 5.7 ± 0.5
[natGa]HBED-CC-Ahx-KuE 6.1 ± 0.8
DOTA-FFK(Sub-KuE) (10) 13.1 ± 2.3
[natGa]DOTA-FFK(Sub-KuE) (natGa-10) 29.5 ± 6.6
[natLu]DOTA-FFK(Sub-KuE) (natLu-10) 54.7 ± 6.1
DOTAGA-FFK(Sub-KuE) (11) 10.2 ± 1.5
[natGa]DOTAGA-FFK(Sub-KuE) (natGa-11) 12.1 ± 3.9
[natLu]DOTAGA-FFK(Sub-KuE) (natLu-11) 15.1 ± 1.5
DOTAGA-ffk(Sub-KuE) (12) 13.9 ± 0.4
[natGa]DOTAGA-ffk(Sub-KuE) (natGa-12) 15.9 ± 0.5
[natLu]DOTAGA-ffk(Sub-KuE) (natLu-12) 13.1 ± 2.2
Binding assays were performed using LNCaP cells (150,000/well) and ([125I]I-BA)
KuE (c = 0.2 nM) as the radioligand. Cells were incubated in HBSS (1% BSA) at 4°C
for 1 h. Data are expressed as mean ± SD (n = 3).
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take of ([125I]I-BA)KuE, that was always assayed in paral-
lel as an external reference. All DOTA and DOTAGA-
coupled ligands showed a lower internalization efficiency
compared to the radioiodinated reference compound,
whereas [68Ga]HBED-CC-Ahx-KuE was internalized al-
most to the same degree as ([125I]I-BA)KuE.
Determination of lipophilicity
The partition coefficient logP between n-octanol and
PBS was determined for the compounds listed in Table 3
using the shake flask method. All compounds are highly
hydrophilic, with the DOTAGA compounds being up to
one order of magnitude more hydrophilic than theFigure 5 Cell binding and internalization kinetics of 177Lu-10
and 177Lu-11 in LNCaP cells. In PLL-coated plates, 125,000 cells/
well were incubated with the respective radioligand (c = 0.5 nM) at
37°C in DMEM-F12 (5% BSA). The total cellular activity was corrected
for non-specific binding (10 μM PMPA). All data are expressed as
mean ± SD (n = 3).corresponding DOTA analogues. Amongst all com-
pounds tested, [68Ga]HBED-CC-Ahx-KuE was the most
hydrophilic compound.
Metabolite analysis
The stability of 177Lu-10 and 177Lu-11 was investigated
by incubation in human serum for 48 h at 37°C and by
DTPA challenge (0.4 M, RT, 48 h) and subsequent TLC
analysis. Release of 177LuIII from the complexes was not
observed under the respective experimental conditions
in the examined time frame.
To investigate the influence of the amino acid com-
position of the spacer (KFF vs kff ) on the metabolic sta-
bility in vivo, tissue homogenates and body fluids of
mice injected with 68Ga-11 and 68Ga-12 were analysed
by radio-HPLC. Representative HPLC profiles of extracts
and body fluids are shown in Figure 6. Extraction effi-
ciencies from the blood and from the kidney were 56%
and 43% for 68Ga-11 and 61% and 62% for 68Ga-12, re-
spectively. Rapid in vivo degradation was observed for
68Ga-11 consisting of the L-amino acid tripeptide FFK,
resulting in only 21% intact tracer in blood at 0.5 h.
68Ga-12 that consists of the D-amino acid tripeptide ffk,
was found to be stable in blood (100% intact tracer) at
0.5 h p.i..
Biodistribution and small-animal PET studies
A comparison of the biodistribution of compounds
68Ga-11, 68Ga-12 and the reference [68Ga]HBED-CC-
Ahx-KuE in LNCaP-tumour-bearing CD-1 nu/nu mice
(1 h p.i.) is shown in Figure 7.
Comparative static PET scans were performed with
68Ga-10, 68Ga-11, 68Ga-12 and [68Ga]HBED-CC-Ahx-
KuE in the same animal model for 15 min at 1 h p.i.. The
maximum intensity projections depicted in Figure 8 con-
firm higher tumour-to-background ratios for 68Ga-11 (c)
compared to the respective DOTA analogue 68Ga-10 (b).
In agreement with the results obtained from the biodistri-
bution (Figure 7), the metabolically stable 68Ga-12 (d)
exhibits increased tumour accumulation and a lower un-
specific whole body uptake and tumour-to-background ra-
tios even higher than those of the reference compound
[68Ga]HBED-CC-Ahx-KuE (a). That tracer uptake into
tumour and kidneys is specific and PSMA mediated [18],
as illustrated by the blocking experiment with PMPA
(8 mg/kg) (Figure 8d′).
In addition, the biodistribution kinetics of 68Ga-10,
68Ga-11, 68Ga-12, and the reference compound [68Ga]
HBED-CC-Ahx-KuE were investigated by carrying out
dynamic μPET scans over a period of 1.5 h in CD-1 nu/
nu mice bearing LNCaP tumour xenografts (Figure 9).
Despite the somewhat lower individual tumour uptake
of 68Ga-12 observed in this μPET-study, the markedly
enhanced clearance of this compound from non-target
Table 2 Internalization of radiometalated ligands in
percentage of external reference ([125I]I-BA)KuE
Ligand Internalization (1 h)
in % of ([125I]I-BA)KuE
[68Ga]HBED-CC-Ahx-KuE 91.1 ± 1.7
[68Ga]DOTA-FFK(Sub-KuE) (68Ga-10) 14.6 ± 0.8
[177Lu]DOTA-FFK(Sub-KuE) (177Lu-10) 19.3 ± 0.9
[68Ga]DOTAGA-FFK(Sub-KuE) (68Ga-11) 28.4 ± 0.7
[177Lu]DOTAGA-FFK(Sub-KuE) (177Lu-11) 36.1 ± 1.1
[68Ga]DOTAGA-ffk(Sub-KuE) (68Ga-12) 42.5 ± 1.7
[177Lu]DOTAGA-ffk(Sub-KuE) (177Lu-12) 44.4 ± 1.8
Data is corrected for unspecific binding, c = 0.2 nM for 68Ga, c = 0.5 nM for
177Lu compounds, 37°C, 1 h, 125,000 cells/well, PLL-coated plates.
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68Ga-12 compared to [68Ga]HBED-CC-Ahx-KuE.Discussion
Due to the consistent overexpression of PSMA in espe-
cially hormone-refractory and metastatic prostate cancer,
this cell surface enzyme represents an excellent target
for high-contrast PET imaging and also for therapeutic
applications. The currently available PSMA-targeted ra-
diopharmaceuticals are highly optimized either for im-
aging [36,37] or endoradiotherapeutic applications [25],
but so far none of the compounds was evaluated for a
theranostic concept. Our approach was therefore fo-
cused on the development of a PSMA ligand allowing
for both, complexation with, e.g. 68Ga or 111In for PET
or SPECT and with therapeutic M3+-radiometals, e.g.
177Lu, 90Y or 225Ac for endoradiotherapy. The most fre-
quently used chelator for this purpose is DOTA, and re-
cently, a first KuE-based DOTA-conjugated PSMA
inhibitor (68Ga-10, [17]) has been described. In a
comparative preclinical evaluation with [68Ga]HBED-
CC-Ahx-KuE [18], 68Ga-10 showed significantly lower
tumour uptake than [68Ga]HBED-CC-Ahx-KuE. How-
ever, since 68Ga-10 may be labelled with a broad palette
of diagnostic and therapeutic radiometals, whereas
[68Ga]HBED-CC-Ahx-KuE may not, we used 68Ga-10Table 3 Lipophilicity of the radiolabelled ligands
(logP(o/w); distribution coefficient in n-octanol/PBS)
Ligand logP(o/w)
[68Ga]HBED-CC-Ahx-KuE −4.1 ± 0.1
[68Ga]DOTA-FFK(Sub-KuE) (68Ga-10) −3.1 ± 0.2
[177Lu]DOTA-FFK(Sub-KuE) (177Lu-10) −2.7 ± 0.02
[68Ga]DOTAGA-FFK/ffk(Sub-KuE) (68Ga-11/12)a −3.6 ± 0.1
[177Lu]DOTAGA-FFK/ffk(Sub-KuE) (177Lu-11/12)a −3.9 ± 0.1
Data are expressed as mean ± SD (n =6). aDetermined for 68Ga-11
and 177Lu-11.as a starting point for the development of improved
PSMA-targeted theranostics.
In a first attempt to improve the pharmacokinetics of
the DOTA-coupled PSMA ligand 10, we increased the
hydrophilicity of the ligand by substitution of DOTA by
DOTAGA, resulting in 11. Although [68Ga]HBED-CC-
Ahx-KuE contains the lipophilic HBED-CC chelator,
which improves binding affinity [18], a logP of -4.1 ± 0.1
was determined, revealing a significantly higher hydro-
philicity compared to logP = -3.1 ± 0.2 for 68Ga-10. The
hydrophilicity of the 68Ga-labelled DOTAGA-coupled
ligand 11 increased to log P = -3.6 ± 0.1. For 68Ga, as
well as 177Lu labelling, the DOTA-conjugated ligand 10Figure 6 Exemplary radio-HPLC analyses of extracts from
homogenized organs and body fluids. HPLC-traces of CD-1 nu/nu
mice (0.5 h p.i. of 40 to 45 MBq of 68Ga labelled tracer, Chromolith
column, flow rate 3 mL/min) for 68Ga-11 (3% for 3 min, 3% to 95%
in 6 min, 95% for 3 min) and 68Ga-12 (3% to 95% in 6 min, 95%
for 3 min).
Figure 7 Biodistribution data (in % ID/g) at 1 h p.i.. The biodistribution of 68Ga-12 in LNCaP tumour xenograft bearing CD-1 nu/nu mice
(n =5) in comparison to 68Ga-11 (n = 5) and [68Ga]HBED-CC-Ahx-KuE (n = 4).
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ited no differences in labelling efficiency.
To examine the metabolic stability of these new PSMA
tracers in vivo, CD-1 nu/nu mice were injected with the
68Ga-labelled ligand 11. Due to its L-amino acid spacer,
68Ga-11 was rapidly metabolized. Furthermore, we demon-
strated that fast metabolization of 68Ga-10 and 68Ga-11 re-
sulted in discontinuous clearance kinetics and low tumour
accumulation in vivo (Figure 7, 8, 9). This most likely
explains the finding in the literature, that despite moderate
affinity towards PSMA (IC50 = 29.5 ± 6.6 nM) the DOTA
ligand 68Ga-10 exhibited unfavourable tumour targeting
compared to [68Ga]HBED-CC-Ahx-KuE. Further, weFigure 8 Maximum intensity projections (MIP) of μPET scans. MIP (1 h
carcinoma xenograft bearing mice (right shoulder) after injection of approx
(d) 68Ga-12, (d′) 68Ga-12 + blocking (8 mg/kg PMPA).observed significant inter-individual differences in meta-
bolization kinetics for 68Ga-11 (with its L-amino acid spa-
cer) in mice, which might explain inconsistent in vivo
results obtained with PSMA ligands with L-amino acid
spacers [38,39]. To overcome the problem of rapid proteo-
lytic cleavage of radiolabelled 11, we substituted the L-
amino acid spacer (FFK) by its D-amino acids counterpart
ffk (12) resulting in high metabolic stability in vivo.
In addition to the improvement in metabolic stability
for 12, we found that the DOTAGA-conjugated ligands
11 and 12, as well as their gallium(III) and lutetium(III)
complexes, showed a significantly increased affinity
towards PSMA on LNCaP cells compared to the DOTA-p.i. for 15 min, 0% to 6% ID/mL) of five LNCaP human prostate
imately 15 MBq (a) [68Ga]HBED-CC-Ahx-KuE, (b) 68Ga-10, (c) 68Ga-11,
Figure 9 Time-activity-curves (logarithmic plot) in % ID/mL for
blood pool (heart), muscle, kidney and tumour. Graphs for (a)
[68Ga]HBED-CC-Ahx-KuE, (b) 68Ga-10, (c) 68Ga-11, (d) 68Ga-12 are
derived from dynamic small animal PET data.
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10 (IC50 = 54.7 ± 6.1 nM) was less affine compared to
natLu-11 (15.1 ± 1.5 nM) or natLu-12 (13.1 ± 2.2 nM).
This finding most likely is due to the increased charge of
the DOTAGA-ligands. In our competitive binding assay,
unlike reported for other assays in the literature [18], a
significantly lower affinity for natGa-10 (IC50 of 29.5 ±
6.6 nM) was determined compared to [natGa]HBED-CC-
Ahx-KuE (IC50 = 6.1 ± 0.8 nM).
As expected from their enhanced PSMA affinities,
the DOTAGA ligands 68Ga/177Lu-11 and 68Ga/177Lu-12
showed up to twofold increased internalization com-
pared to the corresponding DOTA ligands 68Ga/177Lu-
10. Interestingly, 68Ga/177Lu-12 with the ffk spacer
showed a higher internalization rate than ligand 11
with the FFK spacer. Blocking experiments with PMPA
highlight the high PSMA-specificity of these tracers.
Accordingly, the pharmacokinetics and tumour uptake
of the new ligands, i.e. 68Ga-12 in LNCaP-tumour bear-
ing CD-1 nu/nu mice could be enhanced (Figure 7). The
metabolically instable 68Ga-11 revealed higher activity
levels in the blood pool and almost all organs, whereas
the metabolically stable tracer 68Ga-12 displayed no sig-
nificant uptake in the gastrointestinal tract (<0.5% ID/g)
and high kidney accumulation of 96 ± 45% ID/g. The
kidney uptake is PSMA-specific, as shown in the blocking
experiment (Figure 8d′). Although [68Ga]HBED-CC-Ahx-
KuE showed a higher affinity and increased internalization
rate compared to 68Ga-12, the in vivo biodistribution
(Figure 7) and μPET imaging studies (Figure 8) revealed
favourable in vivo characteristics for 68Ga-12. The uptake
of 68Ga-12 into the PSMA positive LNCaP tumour xeno-
graft was somewhat increased compared to that of [68Ga]
HBED-CC-Ahx-KuE (5.2 ± 1.2% vs. 4.7 ± 0.2% ID/g, re-
spectively). Further, [68Ga]HBED-CC-Ahx-KuE showed
enhanced tracer uptake into the lung (1.9 ± 0.4% vs. 1.1 ±
0.3% ID/g), liver (0.5 ± 0.1 vs. 0.2 ± 0.04% ID/g), spleen
(14.7 ± 2.6 vs. 5.5 ± 0.2% ID/g) and pancreas (0.9 ± 0.2 vs.
0.4 ± 0.1% ID/g). Therefore, the lower unspecific uptake of
68Ga-12 compared to [68Ga]HBED-CC-Ahx-KuE resulted
in higher tumour-to-background ratios, i.e. tumour-to-
blood (17.0 ± 0.5 vs. 12.5 ± 0.7) and tumour-to-skeletal
muscle (19.8 ± 0.7 vs. 16.2 ± 0.1).
After the initial distribution phase of a radiopharma-
ceutical, straightforward clearance kinetics is typically
characterized by a linear decrease in a semilogarithmic
plot (two-compartment model). Interestingly, this kinetic
profile (Figure 9) was only observed for 68Ga-12, whereas
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http://www.ejnmmires.com/content/4/1/63all other tracers (or their radiolabelled metabolites) exhibit
unspecific retention or redistribution effects, resulting in
non-linear kinetics (e.g. between 10 and 60 min) in the
semilogarithmic plot. Considering the time-activity curves,
it is worth noting that based on the kinetics of the refer-
ence compound [68Ga]HBED-CC-Ahx-KuE redistribution
from tissues and compartments with unspecific uptake in
the early phase seems likely and might explain the discon-
tinuous clearance and increasing tumour uptake at later
time points. The uptake of DOTA conjugate 68Ga-10 in
the tumour is continuously increasing over time, but sur-
prisingly without a corresponding decline of activity in
muscle or blood (as measured over the heart). In contrast,
a slow washout from the target and non-target tissues was
observed for 68Ga-11. Most likely as a result of its meta-
bolic instability, 68Ga-11 exhibited discontinuous and only
moderate clearance kinetics. However, 68Ga-12 shows typ-
ical and nearly ideal in vivo pharmacokinetics, both for the
target tissue (tumour and kidney) as well as the non-target
tissue muscle and the blood. Equivalent to our DOTAGA
ligand 12, the biodistribution of a naphthyl-containing
[177Lu]DOTA-PSMA ligand was described recently [40],
therefore, we assume that 177Lu-12 also reveals favourable
properties in vivo.Conclusions
Compared to the metabolically unstable DOTA conju-
gate 10 and DOTAGA-conjugate 11, 68Ga- and 177Lu-12
were found to be rapidly internalized into PSMA ex-
pressing cells, to have a favourable pharmacokinetic pro-
file in vivo and only negligible unspecific uptake with no
redistribution in vivo. Based on the DOTAGA chelator
and the use of a D-amino acid spacer, compound 12
possesses remarkable potential for a PSMA based thera-
nostics concept and is a suitable lead structure for the
continuing development of PSMA ligands with further
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